Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials-Reference-Cited by-同舟云学术

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials

Published:2023-09 Issue: Volume:190 Page:112945
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Raimondi Alessandra^ORCID,Nichetti Federico^ORCID,Stahler Arndt^ORCID,Wasan Harpreet S.,Aranda Enrique,Randon Giovanni,Kurreck Annika^ORCID,Meade Angela M.,Díaz-Rubio Eduardo,Niger Monica,Stintzing Sebastian^ORCID,Palermo Federica,Trarbach Tanja,Prisciandaro Michele^ORCID,Sommerhäuser Greta,Fisher David,Morano Federica^ORCID,Pietrantonio Filippo^ORCID,Modest Dominik P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Cervantes;Ann Oncol,2023

2. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study;Tournigand;J Clin Oncol,2006

3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study;Diaz-Rubio;Oncologist,2012

4. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? the GERCOR OPTIMOX2 study;Chibaudel;J Clin Oncol,2009

5. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial;Adams;Lancet Oncol,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of lidocaine pumped through hepatic artery to relieve pain of hepatic artery infusion chemotherapy;Frontiers in Surgery;2024-08-07

2. Targeting the EGFR signalling pathway in metastatic colorectal cancer;The Lancet Gastroenterology & Hepatology;2024-07

3. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial;ESMO Open;2024-07

4. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID);Cancer Medicine;2024-04

5. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer;JAMA Network Open;2024-01-08